326 related articles for article (PubMed ID: 24130112)
21. High-throughput measurements of the optical redox ratio using a commercial microplate reader.
Cannon TM; Shah AT; Walsh AJ; Skala MC
J Biomed Opt; 2015 Jan; 20(1):010503. PubMed ID: 25634108
[TBL] [Abstract][Full Text] [Related]
22. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
23. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
25. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
26. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
27. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.
von Schwarzenberg K; Lajtos T; Simon L; Müller R; Vereb G; Vollmar AM
Mol Oncol; 2014 Feb; 8(1):9-19. PubMed ID: 24055142
[TBL] [Abstract][Full Text] [Related]
28. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
[TBL] [Abstract][Full Text] [Related]
29. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
30. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
31. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.
Zhao Y; Liu H; Liu Z; Ding Y; Ledoux SP; Wilson GL; Voellmy R; Lin Y; Lin W; Nahta R; Liu B; Fodstad O; Chen J; Wu Y; Price JE; Tan M
Cancer Res; 2011 Jul; 71(13):4585-97. PubMed ID: 21498634
[TBL] [Abstract][Full Text] [Related]
32. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.
Shi Y; Fan X; Meng W; Deng H; Zhang N; An Z
Breast Cancer Res; 2014 Apr; 16(2):R33. PubMed ID: 24693969
[TBL] [Abstract][Full Text] [Related]
33. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
[TBL] [Abstract][Full Text] [Related]
35. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
37. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
38. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
39. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
[TBL] [Abstract][Full Text] [Related]
40. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
